An emboldened AstraZeneca splurges $95M on a priority review voucher. Where do they need the FDA to hustle up?
AstraZeneca is in a hurry.
We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.
That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.